Capricor Therapeutics (NASDAQ:CAPR) PT Raised to $15.00 at Oppenheimer

Capricor Therapeutics (NASDAQ:CAPR) had its target price lifted by analysts at Oppenheimer from $14.00 to $15.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price would indicate a potential upside of 192.97% from the company’s current price.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reissued a “buy” rating and set a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Capricor Therapeutics Stock Up 0.8 %

Shares of NASDAQ CAPR opened at $5.12 on Tuesday. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $7.28. The stock has a market capitalization of $163.73 million, a PE ratio of -5.89 and a beta of 3.92. The firm has a fifty day moving average of $4.35 and a 200-day moving average of $5.18.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Equities research analysts expect that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares during the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics during the second quarter worth about $426,000. Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Jump Financial LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth about $258,000. Finally, Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $147,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.